While aesthetic new products such as Latisse and Juvederm should help goose growth in 2010, we're even more enthusiastic about Restasis for dry eyes. The product saw a 40% increase in sales during the fourth quarter, which seems to be driven by ongoing detailing efforts to let practitioners know of how widespread dry eye is and its chronic nature.
Translation: Restasis sales dudes and dudettes are making hay while the sun shines. They know they ain't gonna be the only FDA approved dry eye drug foreva.
1 comment:
Hopefully we will see some more effective dry eye drugs this decade...
Post a Comment